US biotech Emergent BioSolutions (NYSE: EBS) revealed it has secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox and mpox product portfolio.
Emergent’s shares closed up 2.8% on Wednesday, and edged up a further 1.2% to $6.01 in pre-market activity today.
This order includes the previously disclosed US government contract modification to procure ACAM2000, (Smallpox and Mpox (Vaccinia) Vaccine, Live), as well as CNJ-016 [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) contract options exercised in 2023 and 2024, Emergent explained.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze